Related Experiment Video
Updated: Feb 8, 2026

Laser Microdissection-Based Protocol for the LC-MS/MS Analysis of the Proteomic Profile of Neuromelanin Granules
Published on: December 16, 2021
Cell- and Tissue-Based Proteome Profiling and Bioimaging with Probes Derived from a Potent AXL Kinase Inhibitor
Binbin Zheng1, Haijun Guo1, Nan Ma1
1School of Pharmacy, Jinan University, Guangzhou City Key Laboratory of Precision Chemical Drug Development, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People's Republic of China, 601 Huangpu Avenue West, Guangzhou, 510632, China.
Abstract:
AXL has been defined as a novel target for cancer therapeutics. However, only a few potent and selective inhibitors targeting AXL are available to date. Recently, our group has developed a lead compound, 9im, capable of displaying potent and specific inhibition of AXL. To further identify the cellular on/off targets, in this study, competitive affinity-based proteome profiling was carried out, leading to the discovery of several unknown cellular targets such as BCAP31, LPCAT3, POR, TM9SF3, SCCPDH and CANX. In addition, trans-cyclooctene (TCO) and acedan-containing probes were developed to image the binding between 9im and its target proteins inside live cells and tumor tissues. These probes would be useful tools in the detection of AXL in various biosystems.
Insights
Researchers identified new targets for the cancer drug AXL, including BCAP31 and LPCAT3. They also developed imaging probes to detect AXL binding in cells and tissues, aiding cancer research.
Area of Science:
- Oncology
- Biochemistry
- Chemical Biology
Background:
- AXL receptor tyrosine kinase is a novel target for cancer therapeutics.
- Limited availability of potent and selective AXL inhibitors hinders therapeutic development.
- Our group previously developed a lead compound, 9im, with potent and specific AXL inhibition.
Purpose of the Study:
- To identify novel cellular targets of the AXL inhibitor 9im.
- To develop imaging probes for visualizing 9im-target interactions in live systems.
- To validate 9im as a tool for detecting AXL in biological contexts.
Main Methods:
- Competitive affinity-based proteome profiling was employed to discover 9im's cellular targets.
- Development of trans-cyclooctene (TCO) and acedan-containing probes for imaging.
- In situ imaging of 9im-protein binding in live cells and tumor tissues.
Main Results:
- Identification of several previously unknown cellular targets for 9im, including BCAP31, LPCAT3, POR, TM9SF3, SCCPDH, and CANX.
- Successful development of TCO and acedan probes for visualizing target engagement.
- Demonstration of probe utility in imaging 9im binding within cellular and tissue environments.
Conclusions:
- The AXL inhibitor 9im engages multiple novel cellular targets beyond AXL.
- Developed imaging probes are effective tools for studying drug-target interactions in complex biological systems.
- These findings provide a foundation for advancing AXL-targeted cancer therapies and diagnostic tools.
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Base Quantities and Derived Quantities
The International Organization for...

